
    
      A single center, open label, randomized, prospective, pilot study of induction and
      maintenance immunosuppression in adult subjects >18 years undergoing orthotopic liver
      transplantation (OLT) with Basiliximab, delayed dose tacrolimus plus mycophenolate mofetil
      and standard of care (SOC) corticosteroids (Group 1) versus basiliximab, delayed dose
      tacrolimus plus mycophenolate mofetil, SOC corticosteroids, with addition of delayed
      maintenance Everolimus at one month post OLT with subsequent mycophenolate mofetil
      minimization (Group 2) versus standard dose tacrolimus plus mycophenolate mofetil plus SOC
      corticosteroids (Group 3; control) with concomitant renal dysfunction prior to OLT.
    
  